CRISPR Therapeutics
NEWS
Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It was another busy week for clinical trial updates and news. Here’s a look.
Despite promising Phase I data for its CRISPR-based allogeneic CAR-T therapy, CRISPR Therapeutics may have a safety issue to contend with.
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.
As usual, it was a busy week for clinical trial updates. Here’s a look.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first two patients in the companies’ ongoing Phase I/II clinical trials of its CRISPR/Cas9 gene-editing therapy CTX001.
JOBS
IN THE PRESS